Testing a new drug for primary membranous nephropathy
Part of Kidney & urinary clinical trials.
This trial tests a new drug called ALXN1920 for adults with primary membranous nephropathy (PMN), a kidney disease where the immune system attacks the kidneys. It is for people at high risk of their disease getting worse, and it compares the new drug added to standard care versus standard care alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of primary membranous nephropathy (PMN) based on a positive anti-PLA2R antibody test (above 20 RU/mL).
- You are at high risk of your disease getting worse — meaning you have high protein levels in your urine (over 3.5 grams per day) and your blood pressure is controlled on certain medications.
- You are already taking a blood pressure medicine like an ACE inhibitor or ARB for at least 8 weeks.
- Your kidney function (eGFR) is above 60 mL/min/1.73 m² based on a standard blood test.
- You are willing to get antibiotics and vaccinations (including for meningitis) as part of the study treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new gel that contains a natural hormone to quiet the immune attack on kidneys. It is for people whose membranous nephropathy is at high risk of getting worse.
This Phase 1 study tests a skin-under-the-bone (subcutaneous) antibody medicine that targets CD20 on certain immune cells. It aims to see safety and how the drug may work in people with primary membranous nephropathy, a kidney disease that can cause high urine protein.
This study tests a new drug called JMT601 for people with primary membranous nephropathy, a kidney condition that causes protein in the urine. The goal is to see if JMT601 is safe and effective in reducing protein loss and protecting kidney function.
This trial tests a new antibody drug (obinutuzumab) against a standard treatment (cyclophosphamide plus steroids) for people with a kidney condition called primary membranous nephropathy that causes protein leakage. The goal is to see which treatment better reduces protein loss and protects kidney function.
This trial tests an investigational drug called budoprutug for people with primary membranous nephropathy, a kidney condition. The goal is to see if the drug can reduce protein in the urine and help protect kidney function.
This trial studies how well rituximab works in primary membranous nephropathy (a kidney condition) either by itself or with corticosteroids (steroids). It aims to see which approach controls protein leakage in the urine and protects kidney function.
Hear when a new Primary Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.